Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme q10)

Abstract

Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.

Description

RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application Ser. No. 61 / 177,241, filed May 11, 2009, entitled “Methods for Treatment of Oncological Disorders Using an Epimetabolic Shifter (Coenzyme Q10)” (Attorney Docket No.: 117732-00601), U.S. Provisional Application Ser. No. 61 / 177,243, filed May 11, 2009, entitled “Methods for Treatment of Oncological Disorders Using Epimetabolic Shifters, Multidimensional Intracellular Molecules or Environmental Influencers” (Attorney Docket No.: 117732-00701), U.S. Provisional Application Ser. No. 61 / 177,244, filed May 11, 2009, entitled “Methods for the Diagnosis of Oncological Disorders Using Epimetabolic Shifters, Multidimensional Intracellular Molecules or Environmental Influencers” (Attorney Docket No.: 117732-00801), U.S. Provisional Application Ser. No. 61 / 177,245, filed May 11, 2009, entitled “Methods for Treatment of Metabolic Disorders Using Epimetabolic Shifters, Multidimensional Intracellular Molecule...

AI Technical Summary

Benefits of technology

[0029]In certain embodiments of the invention, the oncological disorder being treated or prevented is Squamous Cell Carcinoma. In certain other embodiments, the oncological disorder being treated or prevented is Basal Cell Carcinoma. Other embodiments of the invention, the oncological disorder being prevented is SCC, and the method prevents the pre-cancerous lesion actinic keratosis from progressing into SCC. In other embodiments, the oncological disorder being treated or prevented is melanoma.

Problems solved by technology

Cancer is presently one of the leading causes of death in developed nations and is a serious threat to modern society.

While increasingly successful, each of these treatments may cause numerous undesired side effects.

For example, surgery may result in pain, traumatic injury to healthy tissue, and scarring.

These standard treatments often are accompanied by adverse side effects, e.g., nausea, immune suppression, gastric ulceration and secondary tumorigenesis.

Due to its insolubility in water, limited solubility in lipids, and relatively large molecular weight, the efficiency of absorption of orally administered CoQ10 is poor.

In particular, the NCI cites three small studies on the use of CoQ10 as an adjuvant therapy after standard treatment in breast cancer patients, in which some patients appeared to be helped by the treatment, and reiterates that “weaknesses in study design and reporting, however, made it unclear if benefits were caused by the coenzyme Q10 or by something else.” The NCI specifies that “these studies had the following weaknesses: the studies were not randomized or controlled; the patients used other supplements in addition to coenzyme Q10; the patients received standard treatments before or during the coenzyme Q 10 therapy; and details were not reported for all patients in the studies.” The NCI further reports on “anecdotal reports that coenzyme Q10 has helped some cancer patients live longer, including patients with cancers of the pancreas, lung, colon, rectum and prostate,” but states that ‘the patients described in these reports, however, also received treatments other than coenzyme Q10 including chemotherapy, radiation therapy and surgery.”

Images